Sphere Medical Share Discussion Threads

[del44] 01/9/2016 20:22

I recall the CEO stating that none of the major institutions were in the mood for another fund raising and that other alternatives could be looked at...
It is rather nice to know that we are still debt free presently....

[longshanks] 01/9/2016 16:32

FWIW - the technicals are looking positive.

Not for everyone, but I like to use them as a means of establishing decent entry points.

What has got my eye is that this is currently trading at a nice premium above a 200d moving average curve that has flattened out after a prolonged downward trend.

I can't see CE approval being a problem and I would expect the market to start factoring in the imminent arrival of this rubber stamp and the fact that this should kick-start commercialisation proper. In this respect I expect the share price to make a decent recovery back into the low 20's over the next few months.

I am not too happy, however, with the strong likelihood that a significant placing will be required to bring this to profitability; with this I expect vultures to be swooping overhead for some time and you could argue - why buy when there are such forces at work.

The one thing adding speculative interest for me is that they could land a good licensing deal (almost out of the blue) once they gain CE approval for Proxima 4. If it came with significant upfront and milestone payments then such a deal would be transformational and lead the price into the mid 40's very quickly.

[del44] 30/8/2016 18:35

It is a fair point you make and perhaps shows the rather exceedingly relaxed attitude the board of SPHR have for present shareholder value.
I remain a reluctant holder for now!!
But we really need proper sales and a CE approval (which to me is long over due at this stage) quickly.

[longshanks] 30/8/2016 16:15

Rather strange that TD should give a DCF valuation of 10.2p when peeps paid 16p in a placing not too long ago.I know they plan to "review" that tp once P4 has it's CE mark and reached that "inflection point" but if I was paying for this "research", I would be livid.

[timbo003] 30/8/2016 13:14

Updated note from Trinity Delta here:

[longshanks] 30/8/2016 08:55

Steady on Napoleon!Good to see additional sales although the pace of commercialisation is still very slow.I am hopeful that Proxima 4 - when it arrives - will signal the start of serious take-up.I guess this is hinted at in the subtext to the RNS about the addressable market for Proxima due to rise from 10% to 40-50%.

[timbo003] 30/8/2016 07:55

We are marching through Europe now!

[del44] 28/8/2016 20:00

We use the Glucose only version of these on our ICU ward.They can be a little bit tricky at times. Bits go missing and tests have to be done on them manually. They also need to be calibrated manually and they can be annoying when you need it and it has not been tested.
The I Stat still needs to have blood drawn in a syringe still and needs to be updated separately to the patients data system...So yes they are a competitor to Proxima on the ICU but slightly differently in that the Proxima would be attached directly to the patients arm through the art line.

[timbo003] 28/8/2016 08:41

This story is worth following. I suspect it would be to our advantage if this acquisition were to be called off, the uncertainty regarding the destiny of two of the products that will compete directly with Proxima has probably not helped much as Sphere have talked to potential partners (including Alere and Abbott):





Alere’s Epoc and Abbott’s I-Stat bear an uncanny resemblance to one another. They are both hand held point of care blood analysers for use in an ICU setting and direct competitors to Proxima:


……………………………………………

[del44] 01/8/2016 12:59

Share magazine did an article on Friday's issue about possible upgrade with a CE approval...
Nice to see a little bit more blue today...
C'mon with the CE....

[timbo003] 22/7/2016 23:03

There's a new interview with Wolfgang on Proactive investors, he sounds reasonably upbeat (see link below):


In summary the message seems to be:

* Local distributers preferred over one major distributer for Europe
* P4 approval process nearing completion.
* Wales manufacturing facility ready to go.
* On funding, existing large shareholders likely to back Sphere providing there is commercial traction.

[cumnor] 22/7/2016 10:34

First partner is important-they will have done their due diligence before committing staff and resources to this product-so this is quite positive and along with CE mark authorization it will be a big milestone. After that it boils down to how management play it, how reliable, cost effective and time saving (compared to the present situation it certainly is) the product is. If it meets these criteria-and things are looking positive-then further funding will not be an issue and key players will have either snapped the company up or funding from a much higher share price will take place as stakeholders in the field recognize the potential of the product long before advfn posters do. Therefore funding wont be an issue if, as it seems, this small company product(it is generally the Abbotts and J&Js of the world who innovate this kind of thing)works. It is a gamble as it is with any single product developer so my investment is modest. imo

[timbo003] 22/7/2016 10:00

>>Longshanks

Yes they will need further funds in 2017. According to Wolfgang they are not intending to discuss funding with the existing large shareholders until they have the CE mark for Proxima 4, more sales traction and a partner lined up for the USA/ROW. There is a chance that they could negotiate an upfront payment on signing up a marketing partner for P4, but this is not common practice in this particular part of the healthcare industry, so I'm not holding my breath for that.

[longshanks] 22/7/2016 09:19

I note that they anticipate a further fundraising for £10m next year.Still a very long way from any marked commercial traction.

[timbo003] 21/7/2016 20:52

There was an updated research note released today from Trinity Delta which can be accessed here:

[timbo003] 16/7/2016 11:16

This article caught my attention


Not so much for the recall of Alere's INRatio2 PT/INR Monitoring System, but more for the report that Abbot are trying to wiggle of the merger

Casting my mind back to Wolfgang's Shares Mag presentation in the spring and specifically to my notes on the conversation I had with him following the meeting (see link and abstract from the post #895 below), it is not difficult to see the potential significance:




abstract from post 895

We spent some time discussing the competition. I speculated that if Sphere started eating the competitor’s lunch (Abbott, Roche etc) then they might not remain independent for long. Wolfgang agreed that this was a possibility and added that there were some interesting developments in this area that were likely to have an effect on the market, not least the recently announced takeover of Alere by Abbot for $5.8Bn (equivalent to 2.2X annual sales).


Alere’s Epoc and Abbott’s I-Stat bear an uncanny resemblance to one another. They are both hand held point of care blood analysers for use in an ICU setting and direct competitors to Proxima:


……………………………………………








At this stage it is still not clear whether Abbott will retain both devices following the merger, or whether they will (willingly or unwilling) divest one or the other device.

[del44] 12/7/2016 13:02

Good man Tim...but I fear there will just be the same old same old....
Proving to be most disappointing at this stage....
Gone very quite...

[timbo003] 11/7/2016 23:07

Sphere are presenting at Proactiveinvestor on October 6th, I'll be there.

[del44] 18/6/2016 15:56

Sphere Medical CEO, Wolfgang Rencken commented:

“This presents a huge step forward into integrating data from Proxima™ into laboratory information systems and electronic patient records. Partnering with Conworx allows our customers to use one middleware solution for all of their POC connectivity needs and greatly simplifies the implementation of Proxima™ within the hospital.”

Conworx CEO, Roman Rosenkranz, said:
“We are delighted to be able to offer the first interface to an ex-vivo analyser, which provides a seamless connection from the patient right through to the laboratory information system.”

[del44] 18/6/2016 15:54

Excellent find......glad that issue has been implemented....

[timbo003] 18/6/2016 08:22

A small incremental improvement for Proxima connectivity announced this week which seems to have largely gone unnoticed:

[del44] 06/6/2016 14:43

With the pay packet he is on (for a non producing company)....I would be too...:-)
Cheers!!!